Goldman Sachs analyst Corinne Jenkins reiterated a Buy rating and $20.00 price target on Altimmune (NASDAQ: ALT) as Pemvidutide demonstrates ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE